Remove 2017 Remove Pharmacology Remove Safety
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.

Marketing 103
article thumbnail

Advancing AOCs to transform the delivery of RNA therapeutics

European Pharmaceutical Review

mAbs have well-established safety profiles, high specificity and affinity and long half-lives – they have been used in drug development for more than 30 years. Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities.

Safety 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks. Since the first approval in 2017, the FDA’s Office of Tissue and Advanced Therapies (OTAT) has approved 27 cell and gene therapies.

FDA 105
article thumbnail

Regenerative potential: cell?based therapies for heart failure

European Pharmaceutical Review

Pharmacological therapies mainly address symptoms and unfortunately a significant number of patients do not respond adequately, progressing to congestive heart failure and eventually needing a heart transplant. Despite these trials varying in design, they confirmed the feasibility and safety of the procedure. Frontiers in Pharmacology.

article thumbnail

Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study

Legacy MEDSearch

The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days. The FDA-approved randomized IDE trial has been designed to validate the safety and effectiveness of PiCSO.” Major adverse cardiac events and heart failure endpoints will be captured acutely and for up to 3 years.

Medical 52
article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety. Internet] 2017. Sherene has worked in the healthcare sector for more than 20 years, including in several leadership roles at GSK. Lancet HIV. 2023;10(5):e295-e307.

article thumbnail

Beyond animal testing: the rise of organs-on-chips technology

Clarivate

They became integral to physiological and pharmacological research during the 19th century and started to be systematically used for drug development during the 20th century. Since then, animal-based testing has been the gold standard for establishing a drug’s safety and efficacy. Clinical Pharmacology and Therapeutics, 104(6), pp.